X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SBCH: Concerns surface - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Sep 11, 2001

    SBCH: Concerns surface

    SmithKline Beecham Consumer Healthcare (SBCH) is one of the few FMCG companies that had remained insulated from the economic downturn. Infact, in the first six months of FY02 (January-June 2001) sales growth was a significant 21% and bottomline growth was nearly 37%. However, data appearing in the news articles suggests that the company’s sales growth has been marginally negative for the month of July.

    This is a sign that the downturn is slowly catching up with food processing companies as well. If this trend continues then the company may fail to keep up with its 1HFY02 growth rate. Apart from this, another negative to watch out for in the 2HFY02 is that the full impact of the deferred tax would be felt on SBCH during the second half of this year. This is most likely to trim its bottomline growth for the full year FY02. There are also concerns over the parent’s 100% Indian subsidiaries.

    But apart from these negatives the company looks on a solid ground. The company’s brands continue to do well. The change in management doesn’t seem to have made a difference in the company’s dominance of the malted beverage market. The first half performance of the company reflects this. In the previous five years the company’s turnover has grown at a CAGR of 15% and the net profits at a CAGR of 24%. These figures are by far one of the best growth rates posted by an FMCG company. In future, apart from the minor hiccups mentioned above, SBCH is poised to continue its growth momentum.

    (Rs m) FY97 FY98 FY99 FY00 FY01 CAGR
    Gross sales 5,053 5,660 6,456 7,208 8,754 14.7%
    Net profit 469 620 814 976 1,119 24.3%
    NPM (%) 9.3% 11.0% 12.6% 13.5% 12.8%  

    Moreover, beyond 2001, SBCH is poised to reap the advantages of higher productivity through the new plant (to be commissioned in early 2002) and market expansion through lower-priced ‘Viva’ and ‘Maltova’, targeted at smaller town consumers.

    The stock is trading at Rs 436 at a P/e multiple of 18 times projected FY02 earnings (excluding impact of deferred tax). The stock has gained strength over the last couple of months. Though the valuations still look reasonable against the backdrop of SBCH’s growth momentum, deferred tax blues may restrict any upside movement in the short term.

     

     

    Equitymaster requests your view! Post a comment on "SBCH: Concerns surface". Click here!

      
     

    More Views on News

    GSK Consumer: On the Recovery Path (Quarterly Results Update - Detailed)

    Jun 20, 2017

    While GSK consumer reported muted revenue growth, volumes are seen to be recovering.

    GSK Consumer: Price Hike Hurts Volumes (Quarterly Results Update - Detailed)

    Nov 30, 2016

    GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.

    GSK Consumer: Slowdown in demand impacts sales (Quarterly Results Update - Detailed)

    Oct 5, 2016

    GSK Consumer Healthcare has announced the first quarter results of the financial year 2016-2017 (1QFY17). The company's sales declined by 1.4% YoY while net profit rose by 2.9% YoY during the quarter.

    Apex frozen food Ltd. (IPO)

    Aug 21, 2017

    Should you subscribe to the IPO of Apex Frozen Foods Ltd?

    GSK Consumer: A Forgetful Year (Quarterly Results Update - Detailed)

    Jun 1, 2016

    GSK Consumer Healthcare announced its results for the quarter and year ended March 2016. During the quarter, sales and profit came in lower by 9% YoY and 8% YoY respectively.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    GSK CONSUMER SHARE PRICE


    Aug 23, 2017 03:36 PM

    TRACK GSK CONSUMER

    • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    GSK CONSUMER 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE GSK CONSUMER WITH

    MARKET STATS